Sandoz (SDZNY)

Executive Summary

Sandoz, a global leader in generic pharmaceuticals and biosimilars, was spun off from Novartis in 2023 to sharpen its focus on affordable medicines. Headquartered in Holzkirchen, Austria, the company operates across a broad range of therapeutic areas, with a portfolio of 129 commercial products and a strong pipeline. Its core purpose is to pioneer access to high-quality, lower-cost alternatives to originator drugs, serving patients worldwide. As a standalone entity, Sandoz benefits from operational agility and a dedicated strategy to capture growth in the biosimilars market, where it holds a leading position. The company's valuation of ~$34.8 billion reflects its scale and potential, though it faces competition from other generic and biosimilar players. Sandoz's extensive pipeline, including late-stage biosimilars for complex biologics, positions it to capitalize on upcoming patent expiries and drive revenue growth. However, pricing pressures and regulatory hurdles remain key risks. The company's long-term outlook hinges on successful launches and expansion in emerging markets, supported by its established manufacturing and distribution network.

Upcoming Catalysts (preview)

• Q2 2026FDA Decision on Biosimilar Aflibercept (Eylea)80% success
• Q4 2026Launch of Biosimilar Denosumab (Prolia/Xgeva)70% success
• Q3 2026EU Approval for Biosimilar Secukinumab (Cosentyx)60% success